Q2 FY2026 EarningsQ2 FY26 exceeded consensus across all key financial metrics, highlighted by revenue of $752.8M (+37.7% YoY) vs. $661.3M expected and a gross margin of 64.5% vs. 64.4% mean. Diluted GAAP EPS of -$0.47 beat the consensus of -$0.51, driven by a 57% YoY surge in oncology unit volume and $52.3M in favorable prior-period revenue adjustments. Operating cash flow of $95.0M significantly outperformed the $51.0M consensus, reinforcing Natera’s trajectory toward sustained profitability.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Natera(NTRA) the Revenue is 752.75 M (+37.71%), Beat estimate;the EBIT is -75.79 M (+31.33%), Miss estimate;the EPS is -0.47 (+36.49%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.75B37.71%
0.66B20.98%
+0.09B16.73%
EBITMiss expectations
-0.08B31.33%
-0.08B31.89%
-0.00B0.56%
EPSExceed expectations
-0.4736.49%
-0.511430.89%
+0.04145.60%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf